PEDIATRIC HIV/AIDS COHORT STUDIES: ADOLESCENT MASTER PROTOCOL (AMP)

儿科 HIV/艾滋病队列研究:青少年主方案 (AMP)

基本信息

  • 批准号:
    7951181
  • 负责人:
  • 金额:
    $ 5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-03-01 至 2010-06-30
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The advent of potent ART has resulted in the survival into adolescence of an increasing proportion of infants and children with perinatal HIV infection. At the same time, the number of newly HIV-infected infants in the U.S. has decreased dramatically since 1993 with the development of effective means to prevent mother-to child transmission of HIV. Thus, the largest group of children with perinatal HIV infection in the U.S. consists of pre- adolescents and adolescents. Some of these children represent long-term slow-progressors, while others have benefited from potent combination ART. The impact of HIV infection and its treatment on the growth and development of this cohort of children who have been living with HIV infection since birth is not fully known. The PHACS AMP protocol is designed to study the effect of HIV infection on key processes of maturation such as pubertal development, bone growth, fat distribution, and hepatic, renal and cardiovascular functions. In addition, behavior in adolescents plays a major role in adherence to medications, treatment failure, evolution of viral resistance, and secondary transmission of HIV, including the transmission of resistant virus, to others. This knowledge can form the basis for interventions to improve the quality of life of infected children. Unfortunately, the number of HIV-infected infants, children and adolescents worldwide is growing substantially in both resource-poor countries and in countries with increasing levels of health care. Thus the information gained from this study will benefit the increasing number of infected youth worldwide.
这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者(PI)可能从另一个NIH来源获得了主要资金, 因此可以在其他CRISP条目中表示。所列机构为 研究中心,而研究中心不一定是研究者所在的机构。 强效抗逆转录病毒疗法的出现,使越来越多的婴儿和儿童在围产期感染艾滋病毒后能活到青春期。与此同时,自1993年以来,随着预防母婴传播艾滋病毒的有效手段的发展,美国新感染艾滋病毒的婴儿人数急剧下降。因此,美国最大的围产期HIV感染儿童群体由青春期前和青少年组成。其中一些儿童代表长期缓慢进展者,而另一些儿童则受益于有效的联合抗逆转录病毒疗法。艾滋病毒感染及其治疗对这群自出生以来一直感染艾滋病毒的儿童的生长和发育的影响尚不完全清楚。PHACS AMP方案旨在研究HIV感染对成熟关键过程的影响,如青春期发育,骨生长,脂肪分布以及肝,肾和心血管功能。此外,青少年的行为在坚持药物治疗、治疗失败、病毒耐药性的演变以及艾滋病毒的二次传播(包括将耐药病毒传播给他人)方面发挥着重要作用。这些知识可以成为改善受感染儿童生活质量的干预措施的基础。不幸的是,全世界感染艾滋病毒的婴儿、儿童和青少年的人数在资源贫乏的国家和保健水平不断提高的国家都在大幅增加。因此,从这项研究中获得的信息将使全世界越来越多的受感染青年受益。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DOUGLAS WATSON其他文献

DOUGLAS WATSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DOUGLAS WATSON', 18)}}的其他基金

CLINICAL TRIAL: PACTG 1058:INTENSIVE PHARMACOKINETIC STUDIES OF ANTIRETROVIRAL D
临床试验:PACTG 1058:抗逆转录病毒 D 的强化药代动力学研究
  • 批准号:
    7951157
  • 财政年份:
    2009
  • 资助金额:
    $ 5万
  • 项目类别:
PHASE I/II, OPEN LABEL, PHARMACOKINETIC AND SAFETY STUDY OF A NOVEL PROTEASE
新型蛋白酶的 I/II 期、开放标签、药代动力学和安全性研究
  • 批准号:
    7608133
  • 财政年份:
    2007
  • 资助金额:
    $ 5万
  • 项目类别:

相似海外基金

An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
  • 批准号:
    10057526
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
    Grant for R&D
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
  • 批准号:
    490105
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
    Operating Grants
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
  • 批准号:
    2325465
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
  • 批准号:
    10821172
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
  • 批准号:
    10766947
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
  • 批准号:
    10772887
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
  • 批准号:
    10748465
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
  • 批准号:
    10591441
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
  • 批准号:
    491109
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
    Fellowship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了